Načítá se...
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
BACKGROUND: Major depressive disorder (MDD) with concurrent anxiety symptoms may signal a difficult‐to‐treat patient. Brexpiprazole is a serotonin–dopamine activity modulator: a partial agonist at 5‐HT(1A) and dopamine D(2) receptors at similar potency, and an antagonist at 5‐HT(2A) and noradrenalin...
Uloženo v:
| Vydáno v: | Brain Behav |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5064333/ https://ncbi.nlm.nih.gov/pubmed/27781135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/brb3.520 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|